NasdaqGS:RIGLBiotechs
Assessing Rigel Pharmaceuticals (RIGL) Valuation After Strong Q4 And Full Year 2025 Earnings Results
Rigel Pharmaceuticals (RIGL) is back in focus after reporting fourth quarter and full year 2025 results, with revenue of US$69.8 million for the quarter and net income of US$268.07 million.
See our latest analysis for Rigel Pharmaceuticals.
Despite the strong Q4 and full year 2025 earnings, Rigel Pharmaceuticals' recent share price performance has been weak, with a 90 day share price return of 40.99% and a year to date share price return of 30.98%, while the 1 year total shareholder return of...